Cantor Fitzgerald analyst Alethia Young raised her price target for PTC Therapeutics (PTCT) to $81 from $60, while keeping an Overweight rating on the shares. The analyst notes that Roche (RHHBY) has announced that the pivotal FIREFISH study of risdiplam in Type 1 spinal muscular atrophy met the primary endpoint. Young thinks the data is 'highly robust and meaningful for patients with SMA," especially the Type 2 and 3 patients, and adjusted Probably of Success for risdiplam to 100% from 75%. She is confident in a May approval or earlier based on the data generated between FIREFISH and SUNFISH, and thinks that an oral medicine is a game changer in this population taking intrathecal injections. The SMA program is a collaboration between PTC, the SMA Foundation, and Roche.